Navigation Links
AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
Date:11/3/2008

ead oncology compound, AEZS-108 in both endometrial and ovarian cancer. The data also strengthens our belief that increased clinical benefit for patients could be achieved by specifically targeting LHRH-receptor expressing tumors using doxorubicin. Finally, this program remains on track and we expect to disclose full results over the next few months."

About the Phase 2 Program

Entitled, "The antitumoral activity and safety of AEZS-108 (AN-152), a LHRH agonist linked doxorubicin in women with LHRH-receptor positive gynaecological tumors", this European open-label, non-comparative multi-center Phase 2 program has as its primary endpoint, the partial or complete tumor response rate according to RECIST and/or GCIG guidelines. Secondary endpoints include time to progression, survival, toxicity as well as adverse effects. The program will include up to 82 patients (up to 41 with a diagnosis of platinum-resistant ovarian cancer and up to 41 with disseminated endometrial cancer). Patients are administered an intravenous infusion of 267 mg/m2 of AEZS-108 over a period of 2 hours at a constant rate, every Day 1 of a 21-day (3-week) cycle. The proposed duration of the study treatment is six, three-week cycles. Further information on the program is available at http://www.clinicaltrials.gov.

Prior Phase 1 trial results

On June 3, 2007 positive results of an open, multi-center, sequential group, dose-escalation Phase 1 study in various gynaecological cancers were presented at the American Society of Clinical Oncology's (ASCO) Annual Meeting in Chicago, Illinois. 17 patients with LHRH-receptor positive gynaecological cancers were recruited. AEZS-108 was administered by intravenous infusion over two hours at dosages of 10, 20, 40, 80,160 and 267 mg/m2. At 160 mg/m2, six patients had a total of 32 cycles and at 267 mg/m2, seven patients had a total of 27 cycles. Most of the patients had been pretr
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... The Stirling Ultracold Model SU780U ultra-low ... USA, won the Outstanding New Product Award presented on ... and Environmental Repositories (ISBER) at their annual meeting in ... recognizes the company’s development and introduction of the world’s ... was presented to Global Cooling’s CEO Neill Lane by ...
(Date:5/16/2013)... May 16, 2013 Cambridge Healthtech Institute ... August 19-23, 2013 at the Renaissance Waterfront Hotel in ... provide a close-up look at the current strategies and ... bottom-line quality. Leaders in the field will reveal ... produce biopharmaceuticals with greater specificity and efficiency. , “In ...
(Date:5/16/2013)... As the weather warms, women everywhere are waiting for the ... make a statement with fashion, many change their makeup to ... mixes makeup and sweat to produce, and increase acne breakouts. ... warmer months, Adult Acne treatment , Probiotic Action shares ... to deter breakouts. , Recently, an article from ...
(Date:5/16/2013)... 2013 DNA Genotek, a leading provider of ... a sponsorship program in conjunction with the African Society of ... access and reduce the cost of DNA collection ... Human Heredity and Health in Africa (H3 Africa) Initiative and ... aim of the AfSHG is to build the ...
Breaking Biology Technology:Stirling Ultracold Ultra-Low Freezer Wins 2013 Outstanding New Product Award at International Biorepository Conference, Sydney, Australia 2The 2013 Bioprocessing Summit to Bring Together International Leaders to Discuss Today's Bioprocess Issues From Cell Line Selection to Manufacturing in Boston, MA 2Adult Acne Treatment, Probiotic Action Shares New Tips for Women on How to Fight Acne While Wearing Makeup 2DNA Genotek Inc. Announces Spit for Africa Program 2DNA Genotek Inc. Announces Spit for Africa Program 3
... Presbyterian Cancer Center - Dallas,a joint venture between ... installed an Elekta Infinity system, enabling the facility ... (VMAT).,Elekta Infinity is the facility,s first image guided ... patients shortened treatment times with,the highest degree of ...
... Dax Denman Join as Company Enters Commercialization Phase, ... developers of,DIRECT TO ETHANOL(TM), the most advanced third ... the company with the,appointments Greg Schlicht as Senior ... Dax Denman as Senior Program Manager., Mr. ...
... Biotech Ltd. (Amex:,SVA), a leading provider of vaccines ... in Ukraine for its inactivated hepatitis A,vaccine, Healive, ... by,Biolik Biopharmaceutical Company, a vaccine manufacturer located in,Kharkov, ... Biolik will,also market and distribute Healive in Ukraine, ...
Cached Biology Technology:Presbyterian Cancer Center to Offer Cancer Patients High-End VMAT Treatments With the Installation of Elekta Infinity 2Presbyterian Cancer Center to Offer Cancer Patients High-End VMAT Treatments With the Installation of Elekta Infinity 3Algenol Biofuels Further Strengthens Team With Key Appointments 2Sinovac Initiates Clinical Trials for Inactivated Hepatitis A Vaccine in Ukraine 2Sinovac Initiates Clinical Trials for Inactivated Hepatitis A Vaccine in Ukraine 3
(Date:5/17/2013)... Jersey, and City University of New York have invented ... effectively clears organisms to be viewed under microscopes. Visikol ... is one of the few high-quality clearing solutions currently ... Enforcement Administration (DEA) due to its use as a ... for viewing organisms under a microscope. Without them, microscope ...
(Date:5/17/2013)... 2013, Shenzhen, China---- Why Tibetan antelope can live ... In a collaborative research published in Nature ... other institutes provide evidence that some genetic factors ... harsh highland environments. The data in this work ... mechanisms and the biology of other ruminant species. ...
(Date:5/17/2013)... Bethesda, MD The Federation of American Societies for ... of National Institutes of Health (NIH) funding trends highlighting ... to support critical research. The FASEB analysis follows a ... Francis Collins, MD, PhD, who testified that the $1.6 ... to sequestration is "having a substantial impact on the ...
Breaking Biology News(10 mins):New formula invented for microscope viewing, substitutes for federally controlled drug 2New formula invented for microscope viewing, substitutes for federally controlled drug 3The genome sequence of Tibetan antelope sheds new light on high-altitude adaptation 2
... this innovative solar power technology introduces a new paradigm ... in the world-wide effort to reduce greenhouse gases, it ... source of electricity. Yet several obstacles have been undermining ... actors are looking for a new approach towards the ...
... you want to improve the way you eat, the best way ... visualize yourself carrying it out, according to McGill researchers. ... we,ve known that for a while," says Brbel Knuper of McGill,s ... concrete plan about what they are going to do, they are ...
... method can effectively identify a sub-group of never-smoking lung ... increased risk of disease progression or recurrence, US researchers ... Clinic, Rochester, USA, and colleagues, reported the findings at ... February 2011, Lugano, Switzerland. Approximately 8% - ...
Cached Biology News:Floating solar panels 2Floating solar panels 3Quick, easy test identifies aggressive type of lung cancer in never-smokers 2Quick, easy test identifies aggressive type of lung cancer in never-smokers 3